0.22
price up icon4.71%   0.0099
after-market アフターアワーズ: .22
loading
前日終値:
$0.2101
開ける:
$0.219
24時間の取引高:
13.16M
Relative Volume:
0.77
時価総額:
$51.63M
収益:
$48.47M
当期純損益:
$-170.37M
株価収益率:
-0.2934
EPS:
-0.7499
ネットキャッシュフロー:
$-171.35M
1週間 パフォーマンス:
+10.50%
1か月 パフォーマンス:
-39.34%
6か月 パフォーマンス:
-93.41%
1年 パフォーマンス:
-81.67%
1日の値動き範囲:
Value
$0.2112
$0.2388
1週間の範囲:
Value
$0.19
$0.24
52週間の値動き範囲:
Value
$0.1626
$3.87

Gossamer Bio Inc Stock (GOSS) Company Profile

Name
名前
Gossamer Bio Inc
Name
セクター
Healthcare (1111)
Name
電話
(858) 684-1300
Name
住所
3115 MERRYFIELD ROW, SAN DIEGO, CA
Name
職員
162
Name
Twitter
@GossamerBio
Name
次回の収益日
2026-05-21
Name
最新のSEC提出書
Name
GOSS's Discussions on Twitter

Compare GOSS vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
GOSS icon
GOSS
Gossamer Bio Inc
0.22 49.31M 48.47M -170.37M -171.35M -0.7499
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
435.93 110.28B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
634.62 66.98B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
808.43 50.15B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
295.50 39.71B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
154.89 32.22B 742.00K -1.37B -1.07B -7.0731

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-23 ダウングレード Cantor Fitzgerald Overweight → Neutral
2026-02-24 ダウングレード Barclays Overweight → Equal Weight
2026-02-24 ダウングレード Leerink Partners Outperform → Market Perform
2026-02-24 ダウングレード Wedbush Outperform → Neutral
2026-01-28 開始されました Barclays Overweight
2025-09-10 アップグレード UBS Neutral → Buy
2025-07-14 開始されました Scotiabank Sector Outperform
2024-06-25 開始されました Oppenheimer Outperform
2024-04-05 再開されました Wedbush Outperform
2023-07-27 ダウングレード UBS Buy → Neutral
2023-03-07 ダウングレード Raymond James Outperform → Mkt Perform
2023-03-01 開始されました Guggenheim Neutral
2022-12-07 ダウングレード Barclays Overweight → Equal Weight
2022-12-07 ダウングレード JP Morgan Neutral → Underweight
2022-12-07 ダウングレード SMBC Nikko Outperform → Neutral
2022-10-20 開始されました Goldman Buy
2022-09-21 開始されました JP Morgan Neutral
2022-09-19 開始されました Wedbush Outperform
2022-04-18 開始されました Raymond James Outperform
2022-04-06 開始されました UBS Buy
2022-01-10 アップグレード SMBC Nikko Neutral → Outperform
2021-11-09 再開されました Cantor Fitzgerald Overweight
2021-09-21 再開されました Piper Sandler Overweight
2020-06-29 開始されました H.C. Wainwright Buy
2020-04-22 開始されました Piper Sandler Overweight
2020-02-27 開始されました Barclays Overweight
2019-12-03 再開されました BofA/Merrill Buy
2019-10-30 開始されました Berenberg Buy
2019-03-05 開始されました Barclays Overweight
2019-03-05 開始されました BofA/Merrill Buy
2019-03-05 開始されました Evercore ISI Outperform
2019-03-05 開始されました SVB Leerink Outperform
すべてを表示

Gossamer Bio Inc (GOSS) 最新ニュース

pulisher
09:05 AM

Portnoy Law Firm Announces Class Action on Behalf of Gossamer Bio, Inc. Investors - GlobeNewswire

09:05 AM
pulisher
09:00 AM

GOSS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Gossamer Bio, Inc. Securities LawsuitContact The Gross Law Firm - PR Newswire

09:00 AM
pulisher
08:53 AM

GOSS 6-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS – Company AnnouncementFT.com - Financial Times

08:53 AM
pulisher
06:58 AM

GOSS Reiterates by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus

06:58 AM
pulisher
May 25, 2026

Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.

May 25, 2026
pulisher
May 25, 2026

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire

May 25, 2026
pulisher
May 25, 2026

GOSS Stockholders Have Opportunity to Lead Gossamer Bio, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire

May 25, 2026
pulisher
May 24, 2026

GOSSAMER DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Gossamer Bio, Inc. ... - Caledonian Record

May 24, 2026
pulisher
May 24, 2026

GOSSAMER DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW - GlobeNewswire

May 24, 2026
pulisher
May 24, 2026

GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile

May 24, 2026
pulisher
May 23, 2026

GOSS SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile

May 23, 2026
pulisher
May 23, 2026

Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- HBSS - PR Newswire

May 23, 2026
pulisher
May 23, 2026

GOSS 10-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses Ma - The National Law Review

May 23, 2026
pulisher
May 22, 2026

GOSS Investor AlertGossamer Bio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - PR Newswire

May 22, 2026
pulisher
May 22, 2026

Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire

May 22, 2026
pulisher
May 22, 2026

GOSS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - TMX Newsfile

May 22, 2026
pulisher
May 21, 2026

GOSSAMER DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionGOSS - TMX Newsfile

May 21, 2026
pulisher
May 21, 2026

Earnings call transcript: Gossamer Bio Q1 2026 sees revenue beat, EPS miss - Investing.com UK

May 21, 2026
pulisher
May 21, 2026

Gossamer Bio, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:GOSS) 2026-05-21 - Seeking Alpha

May 21, 2026
pulisher
May 21, 2026

GOSS Investor Alert: Gossamer Bio Securities Fraud LawsuitInv - GuruFocus

May 21, 2026
pulisher
May 21, 2026

Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. - GlobeNewswire

May 21, 2026
pulisher
May 21, 2026

GOSSAMER BIO, INC. (GOSS) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by June 1, 2026 - marketscreener.com

May 21, 2026
pulisher
May 21, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 21, 2026
pulisher
May 21, 2026

GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill

May 21, 2026
pulisher
May 20, 2026

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionGOSS - TMX Newsfile

May 20, 2026
pulisher
May 20, 2026

Goldman Sachs Adjusts Outlook for Gossamer Bio (GOSS) - GuruFocus

May 20, 2026
pulisher
May 20, 2026

Robbins LLP Reminds GOSS Investors of the Pending Class - GlobeNewswire

May 20, 2026
pulisher
May 20, 2026

Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2026 Earnings Call Transcript - Insider Monkey

May 20, 2026
pulisher
May 20, 2026

Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire

May 20, 2026
pulisher
May 19, 2026

ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Gossamer Bio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionGOSS - TMX Newsfile

May 19, 2026
pulisher
May 19, 2026

Wedbush Maintains Gossamer Bio(GOSS.US) With Hold Rating, Maintains Target Price $1 - Moomoo

May 19, 2026
pulisher
May 19, 2026

GOSS Maintained by Barclays -- Price Target Lowered to $0.28 - GuruFocus

May 19, 2026
pulisher
May 19, 2026

Gossamer Bio, Inc. (GOSS) Faces Securities Class Action - GlobeNewswire

May 19, 2026
pulisher
May 19, 2026

The Gross Law Firm Reminds Gossamer Bio, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 1, 2026GOSS - Morningstar

May 19, 2026
pulisher
May 19, 2026

Gossamer Bio Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm

May 19, 2026
pulisher
May 19, 2026

GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS - Sahm

May 19, 2026
pulisher
May 19, 2026

Is Gossamer Bio (GOSS) Undervalued After Q1 2026? EPS -$0.20 (mi - GuruFocus

May 19, 2026
pulisher
May 19, 2026

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit - GuruFocus

May 19, 2026
pulisher
May 19, 2026

Gossamer Bio (GOSS) Reports Mixed Results for PROSERA in Q1 2026 Earnings Call - GuruFocus

May 19, 2026
pulisher
May 19, 2026

Key facts: Gossamer Bio voting deals; PROSERA benefit; Q1 loss $46.7M - TradingView

May 19, 2026
pulisher
May 19, 2026

GOSS Stock Chart | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill

May 19, 2026
pulisher
May 19, 2026

GOSS Reports $99.2 Million in Cash Reserves for Future Operations - GuruFocus

May 19, 2026
pulisher
May 19, 2026

Gossamer Bio Q1 Net Loss Expands; Eyes On The Pre-NDA Meeting With FDA For Seralutinib W In Mid-June - RTTNews

May 19, 2026
pulisher
May 18, 2026

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel ... - Caledonian Record

May 18, 2026
pulisher
May 18, 2026

Latham Represents Gossamer Bio Inc in Exchange Offer and Consent Solicitation Transaction - Latham & Watkins LLP

May 18, 2026
pulisher
May 18, 2026

Gossamer targets September 2026 seralutinib NDA filing with potential Q3 2027 approval - MSN

May 18, 2026
pulisher
May 18, 2026

GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bi - GuruFocus

May 18, 2026
pulisher
May 18, 2026

Gossamer Bio Q1 2026 Deep Dive: EPS Misses by 17.6%, Revenue Up 72% - AlphaStreet

May 18, 2026
pulisher
May 18, 2026

GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio Investors With Losses M - GuruFocus

May 18, 2026
pulisher
May 18, 2026

Gossamer Bio shares decline after wider-than-expected Q1 loss despite revenue beat (GOSS) - MSN

May 18, 2026
pulisher
May 18, 2026

Gossamer Bio Q1 2026 Earnings Call Transcript - MarketBeat

May 18, 2026

Gossamer Bio Inc (GOSS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$29.66
price down icon 0.98%
$92.25
price up icon 0.12%
$108.87
price up icon 2.48%
$53.86
price down icon 1.17%
ONC ONC
$302.44
price down icon 2.52%
$154.89
price up icon 2.20%
大文字化:     |  ボリューム (24 時間):